<DOC>
	<DOCNO>NCT01156415</DOCNO>
	<brief_summary>The study assess safety tolerability 0.5 mg/day 1 mg/day sublingual ( tongue ) formulation agomelatine ( AGO178 ) patient Major Depressive Disorder 52-week open-label phase . Cohort I restrict include patient complete previous Novartis agomelatine ( 178C ) Double-blind study . Cohort II include de-novo patient ( participate previous agomelatine 178C study ) open limited time span range approximately June Sept 2010 , point cohort II close enrollment .</brief_summary>
	<brief_title>Open-label Long Term ( 52 Weeks ) Safety Tolerability Agomelatine Sublingual Tablets Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>S 20098</mesh_term>
	<criteria>Key Inclusion Criteria Cohort I : Documentation completion Novartis AGO178C Doubleblind Study MDD patient . Male female adult , 18 71 year age , inclusive ( i.e. , age range Doubleblind Study , upper age limit increase 1year accommodate patient whose age increase Doubleblind Study ) . Female patient continue use effective contraception define doubleblind study protocol . Key Inclusion criterion Cohort II : Male female adult , 18 70 year age , inclusive . Diagnosis MDD , single recurrent episode , accord DSMIV criterion . Current episode ≥4 week . CGISeverity score ≥4 Screening Baseline . Key Exclusion Criteria Cohort I : Concomitant use fluvoxamine . Any significant medical condition emerge Doubleblind Phase previous study , may interfere study participation and/or study assessment assess investigator . Key Exclusion criterion Cohort II : History bipolar disorder ( I II ) , schizophrenia , schizoaffective disorder , eat disorder ( current previous one year ) , obsessivecompulsive disorder . Any current Axis I disorder MDD focus treatment . Substance alcohol abuse last 30 day , dependence last 6 month . Prior exposure agomelatine . Female patient childbearing potential use effective contraception . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>71 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>agomelatine</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>MDD</keyword>
	<keyword>depression</keyword>
</DOC>